期刊文献+

药物洗脱支架对稳定冠心病患者血浆B型脑利钠肽的影响 被引量:2

Effects of drug-eluting stents on B-type natriuretic peptide in patients with stable coronary artery disease
下载PDF
导出
摘要 目的:初步探讨稳定型冠心病(CAD)患者静脉血浆B型利钠肽(BNP)水平在长期药物洗脱支架(DES)植入后的变化以及基线BNP水平与临床事件的关系。方法:研究入选了88例稳定CAD患者,均经冠脉造影(CAG)证实。以微粒子酶免分析法(化学发光法)测定所有入选者血BNP浓度。其中29例在DES植入后进行了CAG复查和BNP测定。随访1年时的死亡、非致死性急性冠脉综合征(ACS)、再次PCI、再次心血管原因入院等不良心血管事件。结果:BNP水平:冠脉造影Gensini评分>33组(44例)的显著高于Gensini评分≤33组(44例)的,P=0.0468。DES植入8月后BNP水平明显降低[(230.43±48.81)∶(149.33±17.49)pg/ml,P=0.0382]。平均随访10.5个月,BNP高水平组死亡、非致死性ACS、再入院和再次PCI率均显著高于低水平组(P=0.001)。结论:稳定CAD病变程度越重,BNP水平越高,而DES植入8月后BNP水平降低可能反映了心功能的改善;基线BNP水平对稳定CAD心血管事件可能有重要预测价值。 Objective:To observe the changes of BNP levels after drug-eluting stent (DES)implantation and to explore the prognostic effect of BNP levels on cardiovascular events in patients with stable coronary artery disease (CAD).Methods:Between 2007 and 2009,a cohort study involving 88 patients with stable CAD in our hospital was conducted. All patients were proved by coronary angiography (CAG). After DES implantation,CAG and BNP of 29 patients with stable CAD were measured again. Patients were followed-up one year.Results:In higher Gensini (CAG)scores group(44 cases),the BNP levels increased than that of lower Gensini scores group(44 cases),P=0.046.After PCI,BNP levels of 29 patients decreased[(230.43±48.81) pg/ml vs.(149.33±17.49)pg/ml,P=0.0382].After 10.5 months follow-up,patients with higher baseline BNP levels associated with significantly increase of death,nonfatal ACS,repeated PCI and rehospitalization (P=0.001).Conclusion:Results confirms high BNP levels are associated with severity of myocardial ischemia and predict more adverse cardiovascular events in patients with stable CAD after drug-eluting stent implantation.
出处 《心血管康复医学杂志》 CAS 2010年第1期54-57,67,共5页 Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词 冠状动脉疾病 利钠肽 冠状血管造影 支架 Coronary artery disease Natriuretic peptide brain Coronary angiography Stent
  • 相关文献

参考文献9

  • 1殷兆芳,方唯一,任义荣,严毓勤,解玉水,许左隽,顾爱春,黄震华,吴士尧.冠心病患者动静脉血浆B型利钠肽浓度变化及其意义[J].心血管康复医学杂志,2009,18(1):44-46. 被引量:5
  • 2Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease [J]. Am J Cardiol, 1983, 51 (3): 606.
  • 3Mukoyama M, Nakao K, Saito Y, et al. Human brain natriuretic peptide, a novel cardiac hormone [J]. Lancet, 1990, 335 (8692):801-802.
  • 4Hama N, Itoh H, Shirakami G, et al. Rapid ventrieular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction [J]. Circulation, 1995, 92 (6) : 1558-1564.
  • 5de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease [J]. Lancet, 2003, 362 (9380): 316-322.
  • 6任节,段宝祥,毛建华.脑钠肽与心力衰竭[J].心血管康复医学杂志,2005,14(1):78-80. 被引量:19
  • 7Kragelund C, GrOnning B, Omland T, et al. Is N-terminal pro B-type natriuretie peptide (NT-proBNP) a useful screening test for angiographic findings in patients with stable coronary disease [J]? Am Heart J, 2006, 151 (3) : 712e1-712e7.
  • 8Abdullah SM, Khera A, Das SR, et al. Relation of coronary atherosclerosis determined by electron beam computed tomography and plasma levels of n-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (the Dallas heart study) [J]. Am J Cardiol, 2005, 96 (9): 1284-1289.
  • 9McClure SJ, Gall S, Schechter CB, et al. Percutaneous coronary revascularization reduces plasma N- terminal pro- B- type natriuretic peptide concentration in stable coronary artery disease [J]. J Am Coll Cardiol, 2007, 49 (25) : 2394-2397.

二级参考文献23

  • 1Windhausen F, Hirsch A, Sanders GT, et al. N--terminal pro-brain natriuretic peptide for additional risk stratification in patients with non-ST-elevation acute coronary syndrome and an elevated troponin T: an invaslve versus conservative treatment in unstable coronary syndromes (ICTUS) substudy [ J]. Am Heart J, 2007, 153 (4), 450-453.
  • 2Saenger AK, Jaffe AS. The use of biomarkers for the evaluation and treatment of patients with acute coronary syndromes [J]. Med Clin North Am, 2007, 91 (4):657--681.
  • 3Shlipak MG, Ix JH, Bibbins-Domingo K, et al. Biomarkers to predict recurrent cardiovascular disease:the heart and soul study [J]. Am J Med, 2008, 121 (1): 50--57.
  • 4Palazzuoli A, Deckers J, Calabro A. Brain natriuretic peptide and other risk markers for outcome assessment in patients with non-ST-elevation coronary syndromes and preserved systolic function [J].Am J Cardiol, 2006, 98 (10): 1322--1328.
  • 5Morrow DA, de Lemos JA, Sabstilie MS, Evaluation of B-- type natrluretlc peptide for risk assessment in unstable angina/ non-ST-segment elevation myocardial infarction; B-type natriuretie peptide and prognosis in TACTICS--TIMI 18 [J]. J Am CollCardiol, 2003, 41 (8): 1264--1272.
  • 6Sadanandan S, Cannon CP, Chekuri, et al. Association of elevated B--type natriuretic peptide levels with anglographic lindings among patients with unstable angina and non-ST-segment elevation myocardial infarction [J].J Am Coll Cardioh 2004, 44 (3), 564--568.
  • 7Omland T, Persson A, Ng L, et al. N-- terminal pro B-type natriuretic peptide and long-term mortality in acute coronary syn dromes [J]. Circulation, 2002, 106 (23): 2913-2918.
  • 8McClure SJ, Gall S, Schechter CB, at al. Pereutaneous coronary revascularization reduces plasma N--terminal pro-B-type natriuretic peptide concentration in stable coronary artery disease [J]. J Am Coll Cardiol, 2007, 49 (25): 2394--2397.
  • 9Packer M.Survival in patients with chronic heart failure and its potential modification by drug therapy.In Cohn,J.N(ed):Drug treatment of heart failure[M].2nd ed.Secaucus:N J ATC international,1988.273.
  • 10European society of cardiology.Task force for the diagnosis and treatment of chronic heart failure.Guideline for the diagnosis and treatment of chronic heart failure[J].Eur Heart J,2001,22,1527-1560.

共引文献22

同被引文献36

  • 1葛均波,杨巍.冠状动脉内支架内再狭窄的机制认识及防治[J].内科理论与实践,2006,1(1):7-9. 被引量:9
  • 2贾东煜,王贵学.血管支架内再狭窄相关因素与机制的研究进展[J].中国组织工程研究与临床康复,2007,11(35):7061-7064. 被引量:24
  • 3Windhausen F, Hirsch A, Sanders GT, et al. N-terminal pro- brain natriuretic peptide for additional risk strati{ication in pa- tients with non-ST-elevation acute coronary syndrome and an ele- vated troponin T: an Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy [J]. Am Heart J, 2007, 153 (4): 485-492.
  • 4Saenger AK, Jaffe AS. The use of biomarkers for the evaluation and treatment of patients with acute coronary syndromes [J]. MedClinNorthAm, 2007, 91 (4): 657-681.
  • 5Mukoyama M, Nakao K, Saito Y, et al. Human brain natriuretic peptide, a novel cardiac hormone [J]. Lancet, 1990, 335 (8692): 801-802.
  • 6Hama N, Itoh H, Shirakami G, et al. Rapid ventricular induc- tion of brain natriuretic peptide gene expression in experimental acute myocardial infarction [J]. Circulation, 1995, 92 (6) : 1558-1564.
  • 7de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease [J]. Lancet, 2003, 362 (9380): 316-322.
  • 8Kragelund C, Gronning B, Omland T, et al. Is N terminal pro B-type natriuretic peptide (NT-proBNP) a useful screening test for angiographic findings in patients with stable coronary disease [J]. AmHeart J, 2006, 151 (3): 712. e1-712, e7.
  • 9Lyngbaek S, Winkel P, Gotze JP, et al. Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-termi- nal pro-B-type natriuretic peptide [J]. Eur J Prey Cardiol, 2013.
  • 10Camenzind E. Treatment of in-stent restenosis-back to the fu- ture? [J]. NEnglJ Med, 2006, 335 (20): 2149-2151.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部